Literature DB >> 34157934

Association between postnatal weight gain and need for treatment in retinopathy of prematurity.

Ma José Cabañas Poy1, José Bruno Montoro Ronsano1, Félix Castillo Salinas2, Nieves Martín Begué3, Susana Clemente Bautista1, Ma Queralt Gorgas Torner1.   

Abstract

OBJECTIVE: To study the association between gestational age (GA) and weight at birth and the development of retinopathy of prematurity (ROP), and in particular the link between postnatal weight gain during the first 6 weeks and need for ROP treatment.
MATERIAL AND METHODS: Retrospective observational study of premature infants who underwent ophthalmoscopy at Hospital Universitari Vall d'Hebron in Barcelona, Spain, between June 2017 and December 2018. We collected data on obstetric and birth characteristics, comorbidities, GA and weight at birth, and weekly weight for the first 6 weeks.
RESULTS: Ninety patients with a mean ± SD GA of 26.87 ± 1.90 weeks and a mean birth weight of 884.29 ± 227.40 g were studied. The mean weight at 6 weeks was 1656.89 ± 478.51 g, which corresponds to a gain of 776.17 ± 298.12 g. Thirty-seven patients (41.1%) were diagnosed with ROP and nine (10%) needed treatment. Significant predictors of the need for treatment in patients with ROP were GA (p = .018) and weight at 6 weeks (p = .021). Birth weight was not significant (p = .361).
CONCLUSIONS: GA and weight gain during the first 6 weeks of life are significantly associated with the need for treatment in infants with ROP. Sex and birth weight were not significant predictors. Postnatal weight gain at 6 weeks is predictive of the need for ROP treatment.

Entities:  

Keywords:  Retinopathy of prematurity; treatment; weight gain

Year:  2021        PMID: 34157934     DOI: 10.1080/14767058.2021.1940937

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  1 in total

1.  Time to regain birth weight - a marker to predict the severity of retinopathy of prematurity?

Authors:  Ajay Anvekar; Sam Athikarisamy; Shripada Rao; Andy Gill; Elizabeth Nathan; Dorota Doherty; Geoffrey Lam
Journal:  BMC Pediatr       Date:  2021-12-02       Impact factor: 2.125

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.